Thilo J. Zander

On Friday evenings after the stock market closes, the news that nobody is supposed to see come out. LAG3 fail. investor.regeneron.com/news-releases/…

#News for #Investors and #Media: The U.S. FDA has granted accelerated approval for our foundational BCL2 inhibitor in relapsed/refractory mantle cell lymphoma — the first and only in R/R #MCL. Full announcement: ir.beonemedicines.com/news/beone-med… #Oncology #BeOneOnnovator

Making the case for ruxolitinib in CAR T-cell enterocolitis #bmtsm #mmsm @BloodPortfolio ashpublications.org/blood/article/…

Updated mSMART guidelines for relapsed myeloma. This is a major revision. MSMART.org 1) First relapse: Options are BCMA CART, Tec-Dara, BCMA bispecific, or standard triplet. How to choose? See below.

@Blood_Cancers @DrJFriedberg @WilmotCancer if you neglect HD21 - just saying

'The Best Results Ever Reported': @DrJFriedberg, of @WilmotCancer, reflects on the recent FDA approval of nivolumab plus AVD for patients with classic Hodgkin #lymphoma and results from the SWOG S1826 trial. ➡️ buff.ly/48jxLXi

@davidasinclair Faster than expected by whom — the scientists raising their Series A?

Longevity science is accelerating faster than expected

@davidasinclair Let’s wait for the randomized trials in humans. Everything else is hope and speculation.

The question is no longer if we can intervene in aging.
It’s how safely and how many times

@davidasinclair Relax, man. Trump mindset makes you age faster – no matter what pills you take.

Europe

Much ado about nothing. William Shakespeare @LuzernerZeitung

Dose-response study on exercise, sleep and nutrition for life expectancy. With 7 hours of sleep and 30 minutes of exercise per d, the entire potential benefit is achieved. Healthy food is of surprisingly little significance. Sleep and exercise surpass everything else. @TheLancet

MajesTEC-9 with both PFS and OS benefit of Teclistamab monotherapy versus PVD/Kd (in a population 100% Dara and Len-exposed)! We finally will have a great (non-CAR T) option for relapse post frontline Dara-(V)Rd, especially in patients relapsing on continuous Dara-R! Will there be a plateau similar to MajesTEC-3? #mmsm jnj.com/media-center/p…

CARTITUDE-4 PFS & OS Update: 3-Year Follow-up! 5 key takeaways 🧵 #mmsm tinyurl.com/mt6cp3uj

Interesting. Concerned about using Len in every 1L DLBCL pt. Would imagine there would be significant excess tox. But let’s wait for publication. It’s a busy space - will tafa-len-RCHOP have what it takes to carve out a 1st line niche? #lymsm

Tafasitamab + Lenalidomide + R-CHOP. Puh. Hope to see the results soon. Key question: Will CD-19 CAR-T still work for patients that relapse early after Tafa? I am not so sure. #DLBCL

Crans-Montana: EU-coordinated medical evacuations of burn patients from Switzerland are underway. 24 patients are being transferred to hospitals in Belgium, France, Germany and Italy, with transport supported by France, Italy, Luxembourg, Romania and Switzerland. 🧵

#ASH25: Presented by @BeaRazzo @AlGarfall as poster but IMO as imp as any oral abstract #LimiTEC with Tec cessation after 6-9m for RRMM pts in VGPR+ led to 12m PFS ~65% ➡️n=50, 4 pLOT, 90% TCR, 20% w prior BCMA (ide-cel + BlenRep, 50% with no response to BCMA-DT!!) ➡️60% in CR prior to cessation of Tec, median fu 12m after cessation, 12m PFS 68%, OS 90%, PFS ⬆️in those w prior BCMA ➡️BCMA loss/mutation most likely mech of resistance but salvaged by Talq 💡Imp to see if B cell recovery a/w ⬇️hyogamm, ⬇️infections ⬇️IVIG⬆️QOL, #MMRF HORIZON study evaluating similar concept 💡Most PD occurred <6m post cessation, all those with PD <12m post cessation had no response to Tec; I wonder if we extend Tec cessation to only after 12m, it will identify pts who would benefit from reinitiation vs alt salvage #MMSM

Donor 7069 carried TP53 mutation (Li-Fraumeni syndrome) - One donor, 67 clinics, 14 countries, at least 197 children Terrible. Unbelievable. investigations.news-exchange.ebu.ch/donor-7069-tp5…

@Papa_Heme No vaccinations in the US anymore?

How would I ever be able to take care of my patients with myeloma without the 50 guidelines on infectious ppx after CART and BiTEs? I’ll save everyone time IVIG monthly Acyclovir 400 mg BID Bactrim M,W,F For BITEs hold if neutropenic

Plasma fractionation companies entering a golden decade. Expanding indications are driving unprecedented demand. $GRIFOLS $CSL $ADMA $HAE The picks & shovels of the CART & bispecific antibody boom. This deserves @JacobPlieth @bradloncar deep dives.